Lycera Stock

lycera.comHealthcareFounded: 1900Funding to Date: $106.06MM

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer.

Register for Details

For more details on financing and valuation for Lycera, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Lycera.

Register Today

Team

Management Team

Alex Howarth
Chief Financial Officer
William Sibold
Co-Chief Executive Officer & President
Bruce Goldsmith Ph.D
Chief Operating Officer and Chief Business Officer
Paul Sekhri
President, Co-Chief Executive Officer & Board Member
H. Jeffrey Wilkins MD
Chief Medical Officer

Board Members

Jeffrey Leiden Ph.D
Blackstone Life Sciences
Michael Hayden Ph.D
Pablo Cagnoni MD
Robert Kamen Ph.D
Mary Campbell
EDF Ventures
Nina Kjellson
InterWest Partners
Paul Sekhri
Steven Gillis Ph.D
ARCH Venture Partners
Kristina Burow
ARCH Venture Partners
Nicholas Simon
Blackstone Life Sciences
Finny Kuruvilla Ph.D
Blackstone Life Sciences
Timothy Mayleben

Other companies like Lycera in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B